Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D

Journal of Immunology

Volumn 180, Issue 11, 2008, Pages 7338-7348

  Krockenberger, Mathias ^a   Dombrowski, Yvonne ^a   Weidler, Claudia ^a   Ossadnik, Monika ^a   Hönig, Arnd ^a   Häusler, Sebastian ^a   Voigt, Heike ^a   Becker, Jürgen C ^a   Leng, Lin ^c   Steinle, Alexander ^b   Weller, Michael ^d   Bucala, Richard ^c   Dietl, Johannes ^a   Wischhusen, Jörg ^a,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Interdisciplinary Center for Clinical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; NATURAL KILLER CELL RECEPTOR NKG2D; IMMUNOGLOBULIN RECEPTOR; NATURAL KILLER CELL ACTIVATING RECEPTORS; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ASCITES TUMOR; CARCINOGENESIS; CYTOTOXICITY; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NATURAL KILLER T CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; ADULT; AGED; ASCITES; CELL CULTURE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NATURAL KILLER CELL; OVARY TUMOR; TUMOR ESCAPE;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, IMMUNOLOGIC; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 47249093196     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.11.7338     Document Type: Article

References (54)

1. Naora, H., and D. J. Montell. 2005. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer 5: 355-366.
2. Ozols, R., S. Rubin, G. Thomas, and S. Robboy. 1997. Epithelial ovarian cancer. In Principles and Practice of Gynecologic Oncology. W. Hoskins, C. Perez, and R. Young, eds. Lippincott-Raven, Philadelphia, pp. 936-986.
3. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
4. Haskill, S., S. Becker, W. Fowler, and L. Walton. 1982. Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. Br. J. Cancer 45: 728-736.
5. de Visser, K. E., A. Eichten, and L. M. Coussens. 2006. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6: 24-37.
6. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
7. Kelly, M. G., A. B. Alvero, R. Chen, D. A. Silasi, V. M. Abrahams, S. Chan, I. Visintin, T. Rutherford, and G. Mor. 2006. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66: 3859-3868.
8. Wang, X., E. Wang, J. J. Kavanagh, and R. S. Freedman. 2005. Ovarian cancer, the coagulation pathway, and inflammation. J. Transl Med. 3: 25.
9. Omura, G. A., M. F. Brady, H. D. Homesley, E. Yordan, F. J. Major, H. J. Buchsbaum, and R. C. Park. 1991. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9: 1138-1150.
10. Bloom, B. R., and B. Bennett. 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82.
11. Hardman, M. J., A. Waite, L. Zeef, M. Burow, T. Nakayama, and G. S. Ashcroft. 2005. Macrophage migration inhibitory factor a central regulator of wound healing. Am. J. Pathol. 167: 1561-1574.
12. Bemhagen, I., T. Calandra, R. A. Mitchell, S. B. Martin, K. J. Tracey, W. Voelter, K. R. Manogue, A. Cerami, and R. Bucala. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
13. Bucala, R., and E. Lolis. 2005. Macrophage migration inhibitory factor a critical component of autoimmune inflammatory diseases. Drug News Perspect. 18: 417-426.
14. Bemhagen, J., R. Krohn, H. Lue, J. L. Gregory, A. Zemecke, R. R. Koenen, M. Dewor, I. Georgiev, A. Schober, L. Leng, et al. 2007. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13: 587-596.
15. Wada, S., S. Fujimoto, Y. Mizue, and J. Nishihira. 1997. Macrophage migration inhibitory factor in the human ovary: presence in the follicular fluids and production by granulosa cells. Biochem. Mol. Biol. Int. 41: 805-814.
16. Meyer-Siegler, K. L., M. A. Bcllino, and M. Tannenbaum. 2002. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456.
17. Hudson, J. D., M. A. Shoaibi, R. Maestro, A. Camero, G. J. Hannon, and D. H. Beach. 1999. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190: 1375-1382.
18. Fingerle-Rowson, G., O. Petrenko, C. N. Metz, T. G. Forsthuber, R. Mitchell, R. Huss, U. Moll, W. Muller, and R. Bucala. 2003. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc. Natl. Acad. Sci. USA 100: 9354-9359.
19. Liao, H., R. Bucala, and R. A. Mitchell. 2003. Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J. Biol. Chem. 278: 76-81.
20. Mitchell, R. A. 2004. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell. Signal. 16: 13-19.
21. Leng, L., C. N. Metz, Y. Fang, J. Xu, S. Donnelly, J. Baugh, T. Delohery, Y. Chen, R. A. Mitchell, and R. Bucala. 2003. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197: 1467-1476.
22. Shi, X., L. Leng, T. Wang, W. Wang, X. Du, J. Li, C. McDonald, Z. Chen, J. W. Murphy, E. Lolis, et al. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606.
23. Al-Hajj, M., M. S. Wicha, A. Benito-Hemandez, S. J. Morrison, and M. F. Clarke. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100: 3983-3988.
24. Jin, L., K. J. Hope, Q. Zhai, F. Smadja-Jofle, and J. E. Dick. 2006. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12: 1167-1174.
25. Petrenko, O., G. Fingerle-Rowson, T. Peng, R. A. Mitchell, and C. N. Metz. 2003. Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J. Biol. Chem. 278: 11078-11085.
26. Apte, R. S., D. Sinha, E. Mayhew, G. J. Wistow, and J. Y. Niederkom. 1998. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J. Immunol. 160: 5693-5696.
27. Repp, A. C, E. S. Mayhew, S. Apte, and J. Y. Niederkom. 2000. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 165: 710-715.
28. Yan, X., R. J. Orentas, and B. D. Johnson. 2006. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 33: 188-198.
29. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190.
30. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
31. Groh, V., R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein, and T. Spies. 1999. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96: 6879-6884.
32. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. Kubin, D. Cosman, S. Ferrone, L. Moretta, and A. Moretta. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicily. Cancer Res. 62: 6178-6186.
33. Groh, V., R. Rhinehart, J. Randolph-Habecker, M. S. Topp, S. R. Riddell, and T. Spies. 2001. Costimulation of CDSαβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2: 255-260.
34. Rosen, D. B., M. Araki, J. A. Hamerman, T. Chen, T. Yamamura, and L. L. Lanier. 2004. A stnictural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173: 2470-2478.'
35. Barber, A., T. Zhang, and C. L. Sentman. 2008. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J. Immunol. 180: 72-78.
36. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC li-gands impair expression of NKG2D and T-cell activation. Nature 419:734-738.
37. Castriconi, R., C. Cantoni, M. Delia Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100: 4120-4125.
38. Eisele, G., J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese. 2006. TGF-β and metalloprotcinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129: 2416-2425.
39. Morand, E. F., M. Leech, and J. Bemhagen. 2006. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat. Rev. Drug Discov. 5: 399-410.
40. Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
41. Valiante, N. M., M. Rengaraju, and G. Trinchieri. 1992. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell. Immunol. 145: 187-198.
42. Meyer-Siegler, K. L., E. C. Leifheit, and P. L. Vera. 2004. Inhibition of macro-phage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4: 34.
43. Sheehy, M. E., A. B. McDermott, S. N. Furlan, P. Klenerman, and D. F. Nixon. 2001. A novel technique for the fiuorometric assessment of T lymphocyte antigen specific lysis. J. Immunol. Methods 249: 99-110.
44. Brown, C. E., C. L. Wright, A. Naranjo, R. P. Vishwanath, W. C. Chang, S. Olivares, J. R. Wagner, L. Bruins, A. Raubitschek, L. J. Cooper, and M. C. Jensen. 2005. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J. Immunol. Methods 297: 39-52.
45. Bernhagen, J., R. A. Mitchell, T. Calandra, W. Voelter, A. Cerami, and R. Bucala. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33: 14144-14155.
46. Uhl, M., S. Aulwurm, J. Wischhusen, M. Weiler, J. Y. Ma, R. Almirez, R. Mangadu, Y. W. Liu, M. Platten, U. Henlinger, et al. 2004. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64: 7954-7961.
47. Agarwal, R., D. H. Whang, A. B. Alvero, I. Visintin, Y. Lai, E. A. Segal, P. Schwartz, D. Ward, T. Rutherford, and G. Mor. 2007. Macrophage migration inhibitory factor expression in ovarian cancer. Am. J. Obstet. Gynecol. 196: 348 e341-e345.
48. Bozza, M., A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189: 341-346.
49. Fan, J., Y. Chen, H. M. Chan, P. K. Tarn, and Y. Ren. 2005. Removing intensity effects and identifying significant genes for Affymetrix arrays in macrophage migration inhibitory factor-suppressed neuroblastoma cells. Proc. Natl. Acad. Sci. USA 102: 17751-17756.
50. Mitchell, R. A., H. Liao, J. Chesney, G. Fingerle-Rowson, J. Baugh, J. David, and R. Bucala. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 99: 345-350.
51. Leech, M., D. Lacey, J. R. Xue, L. Santos, P. Hutchinson, E. Wolvetang, J. R. David, R. Bucala, and E. F. Morand. 2003. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum. 48: 1881-1889.
52. Powell, N. D., T. L. Papenfuss, M. A. McClain, I. E. Gienapp, T. M. Shawler, A. R. Satoskar, and C. C. Whitacre. 2005. Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune en-cephalomyelitis. J. Immunol. 175: 5611-5614.
53. Ren, Y., H. M. Chan, J. Fan, Y. Xie, Y. X. Chen, W. Li, G. P. Jiang, Q. Liu, A. Meinhardt, and P. K. Tarn. 2006. Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma. Oncogene 25: 3501-3508.
54. Roger, T., J. David, M. P. Glauser, and T. Calandra. 2001. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920-924.